[go: up one dir, main page]

PE20010026A1 - Composicion que comprende interferon alfa pegilado - Google Patents

Composicion que comprende interferon alfa pegilado

Info

Publication number
PE20010026A1
PE20010026A1 PE2000000316A PE0003162000A PE20010026A1 PE 20010026 A1 PE20010026 A1 PE 20010026A1 PE 2000000316 A PE2000000316 A PE 2000000316A PE 0003162000 A PE0003162000 A PE 0003162000A PE 20010026 A1 PE20010026 A1 PE 20010026A1
Authority
PE
Peru
Prior art keywords
alpha
pegilado
treatment
composition including
refers
Prior art date
Application number
PE2000000316A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010026A1 publication Critical patent/PE20010026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE AL USO DE INTERFERON ALFA 2a O 2b MODIFICADO CON PEG (CONJUGADOS DE POLIETILENGLICOL) UTILIZANDOSE DE 4,5 µg/Kg A 9 µg/Kg; ADMINISTRADOS UNA VEZ A LA SEMANA POR UN PERIODO DE AL MENOS 3 MESES EN PACIENTES QUE NO HAN RECIBIDO TRATAMIENTO PREVIO O SE LE DIAGNOSTICO RECIENTEMENTE O RECIBIO ALGUN TRATAMIENTO Y ES INTOLERANTE O RESISTENTE AL INTERFERON ALFA. TAMBIEN SE REFIERE AL USO CON FLUORURACILO, INTERLEUCINA-2. EL USO DE INTERFERON ALFA PUEDE SER UTIL PARA EL TRATAMIENTO DE CARCINOMA DE CELULA RENAL METASTASICO POR UN PERIODO COMO PARA LOGRAR UNA RESPUESTA TUMORAL PARCIAL O TOTAL
PE2000000316A 1999-04-08 2000-04-07 Composicion que comprende interferon alfa pegilado PE20010026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
PE20010026A1 true PE20010026A1 (es) 2001-02-05

Family

ID=23106761

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000316A PE20010026A1 (es) 1999-04-08 2000-04-07 Composicion que comprende interferon alfa pegilado

Country Status (23)

Country Link
EP (2) EP1535623B1 (es)
JP (2) JP3712914B2 (es)
CN (1) CN1367702A (es)
AR (1) AR029160A1 (es)
AT (2) ATE419002T1 (es)
AU (2) AU777406B2 (es)
BR (1) BR0009644A (es)
CA (1) CA2303752A1 (es)
CO (1) CO5170412A1 (es)
CY (1) CY1108919T1 (es)
DE (2) DE60041291D1 (es)
DK (2) DK1043025T3 (es)
ES (2) ES2239953T3 (es)
HU (1) HU230271B1 (es)
MX (1) MXPA00003401A (es)
MY (1) MY155221A (es)
NO (1) NO328983B1 (es)
NZ (1) NZ514629A (es)
PE (1) PE20010026A1 (es)
PT (2) PT1043025E (es)
TW (2) TW200526243A (es)
WO (1) WO2000061174A2 (es)
ZA (1) ZA200108169B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239953T3 (es) * 1999-04-08 2005-10-16 Schering Corporation Tratamiento del carcinoma de celulas renales.
WO2007126950A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
EP2552443B1 (en) 2010-04-01 2021-07-14 Oncorena Ab Improved treatment of renal cell carcinoma
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CZ302005B6 (cs) * 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
ES2239953T3 (es) * 1999-04-08 2005-10-16 Schering Corporation Tratamiento del carcinoma de celulas renales.

Also Published As

Publication number Publication date
ATE296638T1 (de) 2005-06-15
JP2001288110A (ja) 2001-10-16
NZ514629A (en) 2004-02-27
HK1032533A1 (en) 2001-07-27
TW200526243A (en) 2005-08-16
ES2319777T3 (es) 2009-05-12
EP1043025B1 (en) 2005-06-01
EP1535623B1 (en) 2008-12-31
MY155221A (en) 2015-09-30
AU4204400A (en) 2000-11-14
AU777406B2 (en) 2004-10-14
JP4721488B2 (ja) 2011-07-13
PT1535623E (pt) 2009-03-19
BR0009644A (pt) 2002-01-08
ATE419002T1 (de) 2009-01-15
DE60041291D1 (de) 2009-02-12
HUP0200781A2 (en) 2002-08-28
JP3712914B2 (ja) 2005-11-02
CY1108919T1 (el) 2014-07-02
CA2303752A1 (en) 2000-10-08
EP1043025A2 (en) 2000-10-11
DE60020442D1 (de) 2005-07-07
WO2000061174A3 (en) 2001-01-25
HK1075417A1 (en) 2005-12-16
HU230271B1 (hu) 2015-11-30
ZA200108169B (en) 2003-01-06
NO20014851D0 (no) 2001-10-05
TWI310314B (en) 2009-06-01
NO328983B1 (no) 2010-07-05
JP2000319196A (ja) 2000-11-21
PT1043025E (pt) 2005-09-30
EP1043025A3 (en) 2000-12-20
AU2004242454B2 (en) 2007-02-15
HUP0200781A3 (en) 2002-09-30
ES2239953T3 (es) 2005-10-16
DE60020442T2 (de) 2006-05-04
AR029160A1 (es) 2003-06-18
AU2004242454A1 (en) 2005-01-20
DK1535623T3 (da) 2009-04-27
NO20014851L (no) 2001-12-07
EP1535623A1 (en) 2005-06-01
CN1367702A (zh) 2002-09-04
WO2000061174A2 (en) 2000-10-19
MXPA00003401A (es) 2002-03-08
DK1043025T3 (da) 2005-07-04
CO5170412A1 (es) 2002-06-27

Similar Documents

Publication Publication Date Title
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
TR200102845T2 (tr) Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
UY26483A1 (es) Activadores de la glucoquinasa transolefinica
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
DE69932510D1 (de) Vaskularisierungsinhibitoren
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IL138665A0 (en) Peptide factor
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
NZ519717A (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
PE20010026A1 (es) Composicion que comprende interferon alfa pegilado
MX2007005581A (es) Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
TR200000157T2 (tr) Nitrik oksit rhinovirüsün bulaşmasını önler.
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
BR0214798A (pt) Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial
BRPI0408468A (pt) métodos para preparação e uso de 1(alfa),24(s)-diidroxivitamina d2
ATE232398T1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
PT1058544E (pt) Inibicao da actividade do tnf
ATE390921T1 (de) Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung
TR200103827T2 (tr) Farmakolojik kompleks

Legal Events

Date Code Title Description
FC Refusal